Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X-TOLE4 open-label extension study of azetukalner in epilepsy
2022-502282-24-00Phase 3Authorised
- Sponsor
- Xenon Pharmaceuticals
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 26
01
Overview
Phase 3, open-label, single-arm trial of azetukalner in epilepsy, Focal onset seizure and generalized tonic-clonic seizure (GTCS), sponsored by Xenon Pharmaceuticals. Primary endpoint: Long-term safety and tolerability. Planned start Feb 2024; status: authorised.
02
Drugs
azetukalner
03
Conditions
epilepsyFocal onset seizuregeneralized tonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on 2022-502282-24-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502282-24-00.